{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:08Z","timestamp":1787027768428,"version":"build-2736575974"},"reference-count":119,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune checkpoint proteins including PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT regulate T-cell functions, which are essential for anti-tumor immunity. Over-expression of these immune checkpoint proteins leads to T-cell exhaustion and a significant impairment of anti-tumor immunity. Rejuvenation of effector T-cell function with immune checkpoint inhibitors (ICI) restores anti-tumor immunity, which translates into clinical efficacy in the frontline and salvage treatment of various hematological malignancies. Efficacy of ICIs is highest in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and NK\/T-cell lymphomas, and modest in immune-privileged-site lymphomas and cutaneous T-cell lymphoma. However, in myeloid malignancies and multiple myeloma, the efficacy of ICIs remains doubtful. In addition to being used as single agents, ICIs have also been combined with other ICIs; as well as chemotherapy, antibody drug conjugates, and epigenetic agents (histone deacetylase inhibitors and hypomethylating agents). More innovative strategies include the use of ICIs in the context of allogeneic haematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy. This review synthesizes current evidence for the use of ICI in different haematological malignancies, and highlights future directions toward biomarker-driven, rationally designed therapeutic combinations.<\/jats:p>","DOI":"10.3390\/cancers18030485","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:12:46Z","timestamp":1770041566000},"page":"485","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3887-047X","authenticated-orcid":false,"given":"Hiu-Ching","family":"Lau","sequence":"first","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Alibrahim, M.N., Carbone, A., Alsaleh, N., and Gloghini, A. (2025). Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies. Cancers, 17.","DOI":"10.3390\/cancers17142292"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: Challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kuzume, A., Chi, S., Yamauchi, N., and Minami, Y. (2020). Immune-Checkpoint Blockade Therapy in Lymphoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155456"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.1016\/j.ctrv.2025.102898","article-title":"Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies","volume":"134","author":"Donzelli","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clml.2025.02.013","article-title":"SOHO State of the Art Updates and Next Questions|Latest Advances in the Management of Primary Mediastinal B-Cell Lymphoma","volume":"25","author":"Lap","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2016.02.004","article-title":"CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling","volume":"28","author":"Porciello","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41586-025-09539-1","article-title":"Proteotoxic stress response drives T cell exhaustion and immune evasion","volume":"647","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","article-title":"Checkpoint inhibitors in hematological malignancies","volume":"10","author":"Ok","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","first-page":"2659","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Biggi, A.F.B., and Elgui de Oliveira, D. (2022). The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers. Biomolecules, 12.","DOI":"10.3390\/biom12030397"},{"key":"ref_16","first-page":"1458","article-title":"PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma","volume":"130","author":"Kil","year":"2017","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000482","DOI":"10.1136\/esmoopen-2018-000482","article-title":"New emerging targets in cancer immunotherapy: The role of LAG3","volume":"4","author":"Puhr","year":"2019","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e14671","DOI":"10.1200\/JCO.2023.41.16_suppl.e14671","article-title":"Safety, tolerability, and pharmacokinetics of HLX26 (an anti-LAG3 antibody) in patients with advanced or metastatic solid tumors or lymphomas","volume":"41","author":"Liu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/bloodadvances.2024015086","article-title":"Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022","volume":"9","author":"Gopal","year":"2025","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a Marker of Self on Red Blood Cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study","volume":"41","author":"Oldenborg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1182\/bloodadvances.2024013338","article-title":"Magrolimab plus rituximab with or without chemotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"8","author":"Maakaron","year":"2024","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in Hematological Malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Satou, A., Takahara, T., and Nakamura, S. (2022). An Update on the Pathology and Molecular Features of Hodgkin Lymphoma. Cancers, 14, (In English).","DOI":"10.3390\/cancers14112647"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: Pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood-2023-184325","article-title":"Pembrolizumab in Relapsed\/Refractory Extranodal NK\/T Cell Lymphoma and Mature T Cell Lymphoma: A Prospective Phase II Study","volume":"142","author":"Chan","year":"2023","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: Efficacy and safety","volume":"97","author":"Chan","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: A multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","article-title":"Treating relapsed\/refractory mature T- and NK-cell neoplasms with tislelizumab: A multicenter open-label phase 2 study","volume":"7","author":"Bachy","year":"2023","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: An open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4143\/crt.2024.531","article-title":"Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study","volume":"57","author":"Yi","year":"2025","journal-title":"Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Uawithya, E., Kulchutisin, K., Jitprapaikulsan, J., Leelakanok, N., and Owattanapanich, W. (2025). Safety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: A systematic review and meta-analysis. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0319714"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2023-179526","article-title":"High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (\u226565) Patients with Previously Untreated Primary CNS Lymphoma","volume":"142","author":"Park","year":"2023","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S\u00e9zary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/10428194.2022.2034155","article-title":"Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study","volume":"63","author":"Ribrag","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post\u2013allogeneic hematopoietic cell transplant: High response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/bloodadvances.2022008403","article-title":"Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Godfrey","year":"2023","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2022-167626","article-title":"Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed\/Refractory Hodgkin Lymphoma","volume":"140","author":"Mei","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2024-205099","article-title":"Immune Checkpoint Inhibitors in Primary Mediastinal B-Cell Lymphoma: A Monocentric Real-Life Experience and Future Potential","volume":"144","author":"Zinzani","year":"2024","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yang, J., Xue, X., Ma, Y., Wang, X., and Xu, C. (2025). Efficacy and safety of PD-1\/PD-L1 inhibitors for natural killer\/T-cell lymphoma: A single-arm meta-analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13812-x"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","article-title":"Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): A phase Ib\/II study","volume":"9","author":"Gao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): A multicentre, single-arm, phase 2 trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-024-01782-8","article-title":"Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma","volume":"9","author":"Xiong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood.2024027109","article-title":"Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed\/refractory NK\/T-cell lymphoma","volume":"146","author":"Kim","year":"2025","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41392-024-01941-x","article-title":"Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: A phase 2 study","volume":"9","author":"Zeng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/bloodadvances.2024014635","article-title":"Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas","volume":"9","author":"Chihara","year":"2025","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2024-205617","article-title":"Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory\/Advanced Cutaneous T Cell Lymphoma","volume":"144","author":"Querfeld","year":"2024","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.1182\/blood-2022-170181","article-title":"Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial","volume":"140","author":"Roberts","year":"2022","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.17448","article-title":"Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study","volume":"194","author":"Moreau","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Frerichs, K.A., Verkleij, C.P.M., Dimopoulos, M.A., Soto, J.A.M., Zweegman, S., Young, M.H., Newhall, K.J., Mutis, T., and van de Donk, N.W.C.J. (2021). Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. Cancers, 13, (In English).","DOI":"10.3390\/cancers13102452"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2018-99-114960","article-title":"Atezolizumab in combination with daratumumab with or without lenalidomide or pomalidomide: A phase Ib study in patients with multiple myeloma","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (\u226565 Years) AML Patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e003392","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed\/Refractory Acute Myeloid Leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High\/High-Risk Myelodysplastic Syndrome (vHR\/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(21)01694-3","article-title":"AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results","volume":"21","author":"Sallman","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: Venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Wang, Y.-X., Wang, A., Su, Y.-F., Wang, J., Li, Y.-H., Li, F., Jing, Y., Xu, L., Wang, Y.-Z., and Zheng, X. (2024). Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: A novel strategy for relapsed\/refractory acute myeloid leukemia. Front. Immunol., 15, (In English).","DOI":"10.3389\/fimmu.2024.1409302"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood-2021-150031","article-title":"Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood-2021-154226","article-title":"Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R\/R) Hodgkin Lymphoma (HL)","volume":"138","author":"Sermer","year":"2021","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/hon.143_2630","article-title":"Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R\/R) Hodgkin lymphoma (HL) and follicular lymphoma (FL)","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e002347","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1002\/mco2.428","article-title":"Long-term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine-plus-camrelizumab epi-immunotherapy and treatment cessation","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1182\/blood-2022-157606","article-title":"Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part","volume":"140","author":"Przespolewski","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hon.2787","article-title":"Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting","volume":"38","author":"Chan","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_90","first-page":"e2400538","article-title":"Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed\/Refractory Hodgkin Lymphoma: A Systematic Review","volume":"11","author":"Almaguer","year":"2025","journal-title":"JCO Glob. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.21037\/atm.2020.04.06","article-title":"Checkpoint inhibitors in primary mediastinal B-cell lymphoma: A step forward in refractory\/relapsing patients?","volume":"8","author":"Balzarotti","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_92","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: Final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1182\/bloodadvances.2023010254","article-title":"Nivolumab combined with brentuximab vedotin for R\/R primary mediastinal large B-cell lymphoma: A 3-year follow-up","volume":"7","author":"Zinzani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Yan, Z., Yao, S., Liu, Y., Zhang, J., Li, P., Wang, H., Chu, J., Zhao, S., and Yao, Z. (2020). Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK\/T-Cell Lymphoma: Case Report and Literature Review. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.608304"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Roccuzzo, G., Giordano, S., Fava, P., Pileri, A., Guglielmo, A., Tonella, L., Sanlorenzo, M., Ribero, S., Fierro, M.T., and Quaglino, P. (2021). Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.733770"},{"key":"ref_98","first-page":"164793","article-title":"Hyperprogression of cutaneous T cell lymphoma after anti\u2013PD-1 treatment","volume":"8","author":"Gao","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/17474086.2025.2469720","article-title":"The past, the present and the future of immune checkpoints inhibitors in multiple myeloma","volume":"18","author":"Tomarchio","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"ref_100","unstructured":"Food, U.S., and Drug, A. (2025, December 15). FDA Alerts Healthcare Professionals and Oncology Clinical Investigators About Two Clinical Trials on Hold Evaluating KEYTRUDA\u00ae (Pembrolizumab) in Patients with Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerts-healthcare-professionals-and-oncology-clinical-investigators-about-two-clinical-trials."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Pophali, P., Varela, J.C., and Rosenblatt, J. (2024). Immune checkpoint blockade in hematological malignancies: Current state and future potential. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1323914"},{"key":"ref_102","unstructured":"Amer, M., Zeidan, Z.X., Sanz, G., Giagounidis, A., Sekeres, M.A., Lao, Z., Deeren, D., Gao, S., Riva, M., and Lee, J.-H. (2025, December 15). Primary Results of the Phase III STIMULUS-MDS2 Study of Sabatolimab + Azacitidine vs. Placebo + Azacitidine as Frontline Therapy for Patients with Higher-Risk MDS or CMML-2. EHA Library: 2024. Available online: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422284\/amer.m.zeidan.primary.results.of.the.phase.iii.stimulus-mds2.study.of.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29198%2Amarker%3D5099%2Afeatured%3D18527."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: The ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/bloodadvances.2024015048","article-title":"Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma","volume":"9","author":"Tabbara","year":"2025","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.2024027197","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: A joint CIBMTR and EBMT analysis","volume":"146","author":"Perales","year":"2025","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.3324\/haematol.2024.284968","article-title":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: A national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"109","author":"Kaphan","year":"2024","journal-title":"Haematologica"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00262-023-03454-y","article-title":"Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent\u2009 + \u2009CAG regimen in patients with relapsed\/refractory acute myeloid leukemia","volume":"72","author":"Gao","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Hu, Y., Wang, Y., Min, K., Zhou, H., and Gao, X. (2024). The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1491330"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.2022017686","article-title":"Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings","volume":"141","author":"Garcia","year":"2023","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., and Bian, Y. (2023). Immune-related adverse events of immune checkpoint inhibitors: A review. Front. Immunol., 14, (In English).","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Casagrande, S., Sopetto, G.B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., and Veccia, A. (2024). Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations. Cancers, 16, (In English).","DOI":"10.3390\/cancers16071440"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Hradska, K., Hajek, R., and Jelinek, T. (2021). Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.733890"},{"key":"ref_115","first-page":"1026","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","article-title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: Phase 1b PORTIA study results","volume":"7","author":"Jaeger","year":"2023","journal-title":"Blood Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1182\/blood-2022-168185","article-title":"Timing of PD-L1 blockade with durvalumab may affect outcomes of CD19 CAR-T cell therapy for relapsed\/Refractory large B-Cell lymphoma","volume":"140","author":"Hirayama","year":"2022","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of Low-Dose Decitabine to Anti\u2013PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/485\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:13:28Z","timestamp":1770700408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":119,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18030485"],"URL":"https:\/\/doi.org\/10.3390\/cancers18030485","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}